ATE395102T1 - In-vitro-synchronisation der kern- und zytoplasma-reifung von oozyten mit addition und entfernung von phosphodiesterase-hemmer typ 3 - Google Patents

In-vitro-synchronisation der kern- und zytoplasma-reifung von oozyten mit addition und entfernung von phosphodiesterase-hemmer typ 3

Info

Publication number
ATE395102T1
ATE395102T1 AT03757724T AT03757724T ATE395102T1 AT E395102 T1 ATE395102 T1 AT E395102T1 AT 03757724 T AT03757724 T AT 03757724T AT 03757724 T AT03757724 T AT 03757724T AT E395102 T1 ATE395102 T1 AT E395102T1
Authority
AT
Austria
Prior art keywords
oocytes
nuclear
maturation
vitro
cytoplasma
Prior art date
Application number
AT03757724T
Other languages
English (en)
Inventor
Johan Smitz
Christian Grondahl
Original Assignee
Novo Nordisk As
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As, Bayer Schering Pharma Ag filed Critical Novo Nordisk As
Application granted granted Critical
Publication of ATE395102T1 publication Critical patent/ATE395102T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0608—Germ cells
    • C12N5/0609—Oocytes, oogonia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/01—Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/105—Insulin-like growth factors [IGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/31—Pituitary sex hormones, e.g. follicle-stimulating hormone [FSH], luteinising hormone [LH]; Chorionic gonadotropins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/39—Steroid hormones
    • C12N2501/392—Sexual steroids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2517/00—Cells related to new breeds of animals
    • C12N2517/10—Conditioning of cells for in vitro fecondation or nuclear transfer

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Reproductive Health (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gynecology & Obstetrics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pregnancy & Childbirth (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT03757724T 2002-10-15 2003-10-15 In-vitro-synchronisation der kern- und zytoplasma-reifung von oozyten mit addition und entfernung von phosphodiesterase-hemmer typ 3 ATE395102T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200201581 2002-10-15

Publications (1)

Publication Number Publication Date
ATE395102T1 true ATE395102T1 (de) 2008-05-15

Family

ID=32103846

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03757724T ATE395102T1 (de) 2002-10-15 2003-10-15 In-vitro-synchronisation der kern- und zytoplasma-reifung von oozyten mit addition und entfernung von phosphodiesterase-hemmer typ 3

Country Status (7)

Country Link
US (2) US20060051863A1 (de)
EP (1) EP1554016B1 (de)
JP (1) JP2006502717A (de)
AT (1) ATE395102T1 (de)
AU (1) AU2003273767A1 (de)
DE (1) DE60321026D1 (de)
WO (1) WO2004035766A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2094086T3 (da) 2006-11-08 2013-11-25 Veritas Bio LLC Indgivelse in vivo af dobbeltstrenget rna til en målcelle
CZ302232B6 (cs) * 2008-07-15 2011-01-05 Ceská zemedelská univerzita v Praze Zpusob zvýšení vývojové schopnosti rostoucích oocytu inhibicí kalcineurinu
EP2430154A4 (de) * 2009-05-14 2014-01-08 Adelaide Res & Innovation Pty Verfahren zur entnahme und reifung von oozyten
WO2016094970A1 (en) * 2014-12-19 2016-06-23 Vrije Universiteit Brussel In vitro maturation of a mammalian cumulus oocyte complex
WO2024024742A1 (ja) * 2022-07-25 2024-02-01 国立大学法人京都大学 霊長類の胎児卵巣細胞から卵胞を誘導する体外培養法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2678506B1 (fr) * 1991-07-01 2000-03-10 Claude Ranoux Procede de fecondation en cycle spontane.
US6110471A (en) * 1996-09-13 2000-08-29 The Board Of Trustees Of The Leland Stanford Junior University Non-hormonal method of contraception
AU1692901A (en) * 1999-11-25 2001-06-04 Novo Nordisk A/S Treatment of human infertility
JP2003529378A (ja) * 2000-04-06 2003-10-07 ノボ ノルディスク アクティーゼルスカブ 卵母細胞の細胞質および核成熟の体外成熟方法

Also Published As

Publication number Publication date
US20060051863A1 (en) 2006-03-09
AU2003273767A1 (en) 2004-05-04
JP2006502717A (ja) 2006-01-26
DE60321026D1 (de) 2008-06-26
EP1554016B1 (de) 2008-05-14
WO2004035766A2 (en) 2004-04-29
WO2004035766A3 (en) 2004-06-03
US20080311656A1 (en) 2008-12-18
EP1554016A2 (de) 2005-07-20

Similar Documents

Publication Publication Date Title
UY26942A1 (es) N-acilsulfonamidas promotoras de la apoptosis
ATE353361T1 (de) Gezielten modifikation der chromatinstruktur
ATE224882T1 (de) Thiazolderivate, verfahren zur herstellung und verwendung
YU83602A (sh) Derivati fenilglicina
ATE260272T1 (de) Beta-aminsäure-derivate zur verwendung als matrix-metalloproteasen- und tna-alpha-inhibitoren
PL357941A1 (pl) Podłożowy monokryształ azotkowy grupy III-V oraz sposób jego wytwarzania i wykorzystania
DK1292320T3 (da) Anvendelse af ekstrakter med immunmodulerende aktivitet fra spermatofytplanter
ID28929A (id) Metoda untuk memproduksi asam akrilat
EA200201056A1 (ru) Новые, обладающие продолжительным действием бетамиметики, способ их получения и их применение в качестве лекарственных средств
DE69722027D1 (de) Kristalle von benzimidazolderivate und verfahren zu ihrer herstellung
DE60035187D1 (de) Verfahren zur Reduzierung des Elektrizitätsverbrauchs eines zellularen Mobiltelefons
DE60042209D1 (de) Enzymatische synthese von deoxyribonucleotiden
DE60124137D1 (de) Aufeinanderfolgende doppelkühlung von brennkammerturbine
SI0920426T1 (en) New thiazole derivatives with phosphodiesterase-inhibiting effect
DE60135481D1 (de) Verwendung von il-13 inhibitoren zur behandlung von tumoren
DE50105968D1 (de) VERFAHREN ZUR HERSTELLUNG VON AlKYLVERBRÜCKTEN LIGANDSYSTEMEN UND ÜBERGANGSMETALLVERBINDUNGEN
HUP0302600A3 (en) Method for in vitro culture of ovarian follicles
DE60321026D1 (de) In-vitro-synchronisation der kern- und zytoplasma-reifung von oozyten mit addition und entfernung von phosphodiesterase-hemmer typ 3
TW200621685A (en) Hydroxynaphthoic acid hydrazide compound and method for preparing the same
DE60129547D1 (de) Verfahren zur kultivierung von mikroorganismen
ATE392413T1 (de) Verfahren zur herstellung von beta-alaninamiden
DK1651754T3 (da) Myelomcellekultur i transferrinfrit medium med lavt jernindhold
ATA6932000A (de) Verfahren zum regeln der entnahmetemperatur von brauchwasser
SE0000382D0 (sv) New process
ATE212969T1 (de) Verfahren zur herstellung von 2-halogenindan-1- onen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties